[ad_1]
- Vericel (NASDAQ:VCEL) has introduced that the U.S. FDA has authorised a supplemental Biologics License Application increasing the MACI® label to incorporate arthroscopic supply of MACI to restore symptomatic single or a number of full-thickness cartilage defects of the knee as much as 4 cm2 in measurement.
- MACI ArthroTM supplies a much less invasive method in comparison with the present method, permitting surgeons to guage and put together the defect website in addition to ship the MACI implant via small incisions utilizing custom-designed MACI Arthro devices.
- MACI is the primary FDA-approved cellularized scaffold product that applies tissue engineering processes to develop cells on scaffolds utilizing wholesome cartilage tissue from the affected person’s personal knee.
- “The approval of MACI Arthro represents another significant milestone in our strategy to provide innovative solutions for patients suffering from pain and dysfunction caused by cartilage defects in the knee,” stated Nick Colangelo, President and CEO of Vericel.
[ad_2]
Source: Seekingalpha